NewAmsterdam Pharma Company N.V. (NAMS) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Naarden, Netherlands. वर्तमान CEO हैं Michael Harvey Davidson Facp..
NAMS के पास है IPO तिथि 2021-02-09, 68 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Capital Marke, बाजार पूंजीकरण $3.96B.
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands, dedicated to developing treatments for metabolic diseases. The company's lead investigational candidate, obicetrapib, is a novel selective inhibitor of Cholesteryl Ester Transfer Protein (CETP) that has demonstrated clinical efficacy in reducing low-density lipoprotein cholesterol (LDL-C) while substantially increasing high-density lipoprotein cholesterol (HDL-C). This dual mechanism addresses a significant unmet medical need in lipid management and cardiovascular disease prevention. NewAmsterdam is focused on advancing obicetrapib through clinical development to improve patient outcomes in metabolic disease populations.
